ESC ranking puts AstraZeneca's Brilinta ahead of Lilly's Effient and clopidogrel
This article was originally published in Scrip
The European Society of Cardiology has backed the use of AstraZeneca's new oral antiplatelet agent ticagrelor (Brilinta/Brilique), giving it its highest class 1 recommendation in its latest guidelines for the treatment of ST-elevation acute myocardial infarction (STEMI).
You may also be interested in...
A Phase III rare-disease hit for Sanofi marks the first of a number of orphan drug read-outs expected in the coming year.
Philadelphia is due to host the American Heart Association (AHA) meeting for the first time from 16-18 November, with the conference taking place in its condensed three-day format for just the second time. Scrip takes a look at the expected highlights.
Shares plummet as ObsEva announces it is discontinuing its IVF program for nolasiban after disappointing Phase III data from a European confirmatory study.